ST Kangmei (600518.SH) released its 2023 annual report. The company's revenue was 4.884 billion yuan,...
According to Zhitong Finance App News, ST Kangmei (600518.SH) released its 2023 annual report. The company's operating income was 4.884 billion yuan, an increase of 16.60% over the previous year; net profit attributable to shareholders of listed companies was 103 million yuan, turning a loss into a profit; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 753 million yuan, narrowing; and basic earnings per share of 0.01 yuan/share.
The company's main products include Chinese medicine tablets, proprietary Chinese medicines, chemicals, health food and food. The company's Chinese medicine tablets are one of the most competitive products. Currently, the company can produce more than 1,000 varieties of Chinese medicine tablets with more than 20,000 specifications; the company has 26 high-quality Chinese medicine tablets, including Sanqi powder, American ginseng, Kangmei lily, and Kangmei Danshen, and has 8 high-tech products in Guangdong Province, including white peony (tablets), dendrobium (tablets, formula granules), and Kangmei Smart Pharmacy.